Implantable cardioverter defibrillator treatment : benefits and pitfalls in the currently indicated population

Leiden Repository

Implantable cardioverter defibrillator treatment : benefits and pitfalls in the currently indicated population

Type: Doctoral Thesis
Title: Implantable cardioverter defibrillator treatment : benefits and pitfalls in the currently indicated population
Author: Borleffs, Carel Jan Willem
Publisher: Department of Cardiology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University
Issue Date: 2010-09-30
Keywords: Implantable cardioverter defibrillator
Sudden death
Ventricular arrythmia
Tachyarrhythmia
Primary prevention
Secondary prevention
Risk stratification
Abstract: On one hand, clinicians have expressed concern that the number-needed-to-treat for primary prevention implantable cardioverter defibrillator (ICD) might be too high and that the population eligible for primary prevention ICD treatment is of such magnitude that ICD therapy will strain financial resources and the pool of trained personnel. On the other hand, the currently implanted population has a relatively low incidence of ventricular arrhythmia. Therefore, additional clinically applicable tools are necessary to aid in the optimal allocation of ICD treatment. The current thesis explores possibilities for risk stratification for mortality and ventricular arrhythmia using easily available clinical parameters and evaluates the usefulness of novel, not routinely acquired parameters. The results of these studies should assist clinicians in the identification of patients who, although currently indicated, should not receive ICD treatments because of ery low risk of ventricular arrhythmia or very high risk of non arrhythmic death. Finally, this thesis clearly maps the drawbacks, accompanying ICD treatment.
Description: Promotores: M.J. Schalij, J.J. Bax, Co-promotor: L. van Erven
With Summary in Dutch
Faculty: LUMC
Citation: Borleffs, C.J.W., 2010, Doctoral Thesis, Leiden University
ISBN: 9789085590637
Sponsor: Astellas Pharma, AstraZeneca BV, Biotronik Nederland BV, Boehringer Ingelheim BV, Boston Scientific BV, GE Healthcare, J.E. Jurriaanse Stichting, MEDA Pharma BV, Merck Sharp & Dohme BV, Novartis Pharma BV, Sanofi-Aventis BV, Schering-Plough BV, Servier Nederland BV, Siemens Nederland NV, St. Jude Medical Nederland BV, Toshiba Medical Systems Nederland
Handle: http://hdl.handle.net/1887/16004
 

Files in this item

Description Size View
application/pdf Full text 5.934Mb View/Open
text/html Published articles Chapter 15 and 16 7.763Kb View/Open
application/pdf Cover 840.8Kb View/Open
application/pdf Title pages_Contents 153.9Kb View/Open
application/pdf Chapter 1 258.5Kb View/Open
application/pdf Chapter 2 426.2Kb View/Open Full text at publisher site
application/pdf Chapter 3 262.4Kb View/Open Full text at publisher site
application/pdf Chapter 4 275.7Kb View/Open Full text at publisher site
application/pdf Chapter 5 263.5Kb View/Open Full text at publisher site
application/pdf Chapter 6 234.2Kb View/Open Full text at publisher site
application/pdf Chapter 7 310.5Kb View/Open
application/pdf Chapter 8 408.9Kb View/Open Full text at publisher site
application/pdf Chapter 9 226.7Kb View/Open Full text at publisher site
application/pdf Chapter 10 217.4Kb View/Open Full text at publisher site
application/pdf Chapter 11 220.2Kb View/Open Full text at publisher site
application/pdf Chapter 12 432.3Kb View/Open
application/pdf Chapter 13 202.8Kb View/Open Full text at publisher site
application/pdf Chapter 14 259.8Kb View/Open Full text at publisher site
application/pdf Chapter 15 262.2Kb View/Open Full text at publisher site
application/pdf Chapter 16 220.8Kb View/Open Full text at publisher site
application/pdf Summary in English 180.7Kb View/Open
application/pdf Summary in Dutch 184.0Kb View/Open
application/pdf Publications_Acknowledgements_Curriculum Vitae 149.6Kb View/Open
application/pdf Propositions 452.2Kb View/Open

This item appears in the following Collection(s)